St. Jude Medical, Inc.
NYSE : STJ

March 20, 2006 16:05 ET

St. Jude Medical Announces First Canadian Implant of St. Jude Medical Rigid Saddle Ring

ST. PAUL, Minn.--(CCNMatthews - Mar 20, 2006) -

St. Jude Medical, Inc. (NYSE:STJ) announced today the first Canadian implant of the St. Jude Medical Rigid Saddle Ring with EZ™ Suture Cuff, a device used for mitral heart valve repair procedures.

Dr. Nicolas Noiseux, from Hotel-Dieu, Montreal Hospital, Montreal, Quebec, performed the implant on a patient with moderate to severe mitral valve regurgitation, a condition where the mitral valve does not close properly, allowing blood to flow backwards in the heart.

"I was pleased with how easy the Rigid Saddle Ring was to implant and suture," said Dr. Noiseux. "The delivery system greatly eased placement of the ring. Also, the EZ™ Suture Cuff allowed me to take large bites in the ring with the suture needles and achieve a very secure attachment of the ring to the mitral annulus. The potential clinical benefits for my patient resulting from the ring's natural saddle shape are very exciting, too."

The St. Jude Medical Rigid Saddle Ring, which recently was approved for Canadian market release, is designed to reduce stress on the valve's leaflets and chords by approximating the mitral valve's natural systolic three-dimensional saddle shape. With its anatomical shape and versatility for either ischemic or degenerative disease, the ring provides surgeons a durable annuloplasty repair alternative.

"St. Jude Medical and its family of heart valve replacement and repair solutions have a track record of global leadership," said George J. Fazio, President of St. Jude Medical's Cardiac Surgery Division. "With its innovative shape designed for durably restoring the natural saddle shape, this full rigid saddle ring is the natural choice for surgeons who want the latest advances in valvular repair technology. The benefits of restoring and maintaining the natural systolic saddle shape of the mitral annulus have been well characterized in the scientific literature. I'm delighted that we can now offer this state-of-the-art heart valve repair device to our Canadian physicians and their patients."

About St. Jude Medical

St. Jude Medical is dedicated to making life better for cardiac, neurological and chronic pain patients worldwide through excellence in medical device technology and services. The Company has five major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiac surgery, cardiology, and neuromodulation. Headquartered in St. Paul, Minnesota, the Company employs approximately 10,000 people worldwide. For more information, please visit www.sjm.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including anticipated future product launches, regulatory approvals, revenues, earnings, market shares, and potential clinical success. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company's control and the risk factors and other cautionary statements described in the Company's filings with the SEC, including the Cautionary Statements described in the Company's Annual Report on Form 10-K filed on March 16, 2006 (see Item 1A on page 15). The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.

Contact Information

  • St. Jude Medical, Inc., St. Paul
    Investor Relations:
    Laura Merriam, 651-766-3029
    or
    Media Relations:
    Kathleen Janasz, 651-415-7042